Carlsmed Q3 Revenue Jumps 65% to $21.6M, Full-Year Guidance Raised to $78-80M
CARL sits 73% above its 52-week low of $8.5.
Summary
Carlsmed reported Q3 2026 revenue of $21.6 million, up 65% year-over-year, and raised full-year 2026 revenue guidance to $78-80 million from $74-78 million. Gross margin improved to 77.3% and the adjusted EBITDA loss narrowed, though the GAAP net loss widened to $12.2 million.
Key Events · Earnings and Guidance · CARL
-
Q3 Revenue Up 65% to $21.6M
Revenue was $21.6 million for the third quarter of 2026, a 65% increase compared to $13.1 million in the third quarter of 2025.
-
Full-Year Guidance Raised to $78-80M
Full-year 2026 revenue guidance was raised to $78 million to $80 million from a prior $74 million to $78 million range, representing over 56% growth at the midpoint versus full-year 2025.
-
Margins Improve, Net Loss Widens
Gross margin rose to 77.3% from 75.9%, and adjusted EBITDA loss narrowed to $7.3 million from $8.2 million. GAAP net loss widened to $12.2 million from $8.5 million, including $2.8 million of executive transition and legal resolution costs.
-
Liquidity of $80.3M at Quarter End
Cash and cash equivalents, restricted cash, short-term investments, and marketable securities totaled $80.3 million as of September 30, 2026.
Analysis · CARL · Industrial Applications And Services
The core story is 65% revenue growth paired with a guidance raise: management now expects $78-80 million for 2026, up from a prior $74-78 million range and implying over 56% growth at the midpoint. Gross margin also improved to 77.3% from 75.9%, and the adjusted EBITDA loss narrowed to $7.3 million from $8.2 million a year ago. Against that, the GAAP net loss widened to $12.2 million from $8.5 million on higher operating spend, including $2.8 million of executive transition and legal resolution costs. With $80.3 million in cash, restricted cash, short-term investments and marketable securities at September 30, the balance sheet funds the current burn, but continued losses mean the $250 million shelf filed in August remains the backstop for future capital needs.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CARL was trading at $14.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $401.6M. The 52-week trading range was $8.50 to $17.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.